Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetracted(2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSato, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 37
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI · Paper page
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
Items 101–200 of 741
Guo, Y., Liu, Y., Shi, C., Wu, T., Cui, Y., Wang, S., Liu, P., Feng, X., He, Y., & Fu, D. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00976-4 · Cited by 42
Atualização do Tratamento Medicamentoso da Osteoporose
Oliveira, L. G., Carneiro, M. L. R. G., de Souza, M. P. G., de Souza, C. G., de Moraes, F. B., & de Camargo, F. L. (2021) · Revista Brasileira de Ortopedia · doi:10.1055/s-0040-1714219 · Cited by 41
Therapeutic Potential of Quercetin as an Antioxidant for Bone-Muscle-Tendon Regeneration and Aging
Kim, J. G., Sharma, A. R., Lee, Y., Chatterjee, S., Choi, Y. J., Rajvansh, R., Chakraborty, C., & Lee, S. (2024) · Aging and Disease · doi:10.14336/ad.2024.0282 · Cited by 41
“Current scientific research on osteoporosis treatment predominantly focuses on examining the balance, differentiation, and regulation mechanisms of osteoblasts and osteoclasts, which play crucial roles in bone creation and resorption [36].”
Zhang, Y., Chai, Y., Pan, X., Shen, H., Wei, X., & Xie, Y. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s187588 · Cited by 41
Atypical femur fractures: current understanding and approach to management
Tile, L., & Cheung, A. M. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20916983 · Cited by 41
The Role of SIRT3 in the Osteoporosis
Hu, S., & Wang, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.893678 · Cited by 40
Xu, B., Radojčić, M. R., Anderson, D., Shi, B., Yao, L., Chen, Y., Feng, S., Lee, J. H., & Chen, L. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000883 · Cited by 39
“Antiosteoporotic drugs are effective treatments recommended by guidelines [28] .”
BackgroundComparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
Kim, Y.-S., Tian, Y., Yang, J., Huser, V., Jin, P., Lambert, C. G., Park, H., You, S. C., Park, R. W., Rijnbeek, P. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68037-8 · Cited by 39
Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis
Prather, C., Adams, E. N., & Zentgraf, W. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa285 · Cited by 39
Li, J., Sun, K., Qi, B., Feng, G., Wang, W., Sun, Q., Zheng, C., Wei, X., & Jia, Y.-S. (2020) · Phytotherapy Research · doi:10.1002/ptr.6908 · Cited by 39
The therapeutic potential of mesenchymal stem cells in treating osteoporosis
Chen, T., Yang, T., Zhang, W., & Shao, J. (2021) · Biological Research · doi:10.1186/s40659-021-00366-y · Cited by 39
“At present, the clinically administered medications to treat OP are divided into three categories according to pathogenesis: basic supplements, antiresorptive agents and bone formation-accelerating agents [9].”
BackgroundRecommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 40
Rahim, F., Zadeh, A. Z., Javanmardi, P., Komolafe, T. E., Khalafi, M., Arjomandi, A., Ghofrani, H. A., & Shirbandi, K. (2023) · BioMedical Engineering OnLine · doi:10.1186/s12938-023-01132-9 · Cited by 39
“ML is a subset of computer science attached to algorithm expansion, authorizing the computer to learn from examples [17, 18].”
MethodHara, T., Hijikata, Y., Matsubara, Y., & Watanabe, N. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013424.pub2 · Cited by 38
Wang, J., Xing, F., Sheng, N., & Xiang, Z. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.883264 · Cited by 38
Che, M., Gong, W., Zhao, Y., & Liu, M. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00219-6 · Cited by 37
“Older people have a higher risk of fracture because of poor bone quality, calcium and vitamin D deficiency (Leder 2017; Qaseem et al. 2017).”
BackgroundRecommendations on screening for primary prevention of fragility fractures
Thériault, G., Limburg, H., Klarenbach, S. W., Reynolds, D. L., Riva, J. J., Thombs, B. D., Tessier, L. A., Grad, R. M., & Wilson, B. J. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.221219 · Cited by 37
“4,12 Screening and preventive pharmacotherapy may, however, lead to un intended consequences (e.g., labelling, stigma, adverse drug effects).”
Liu, J., Lin, X., Sun, L., Zhang, Q., Jiang, Y., Wang, O., Xing, X., Xia, W., & Li, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad732 · Cited by 37
Screening for Geriatric Syndromes
Smith, E. M., & Shah, A. A. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2017.08.002 · Cited by 36
Cong, C., Tian, J., Gao, T., Zhou, C., Wang, Y., Cui, X., & Zhu, L. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s235197 · Cited by 36
Gut Microbiome Signature Are Correlated With Bone Mineral Density Alterations in the Chinese Elders
Wang, Y., Gao, X., Lv, J., Zeng, Y. H., Li, Q., Wang, L., Zhang, Y., Gao, W., & Wang, J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.827575 · Cited by 36
Review of the guideline of the American College of Physicians on the treatment of osteoporosis
Kanis, J. А., Cooper, C. C., Rizzoli, R., & Reginster, J.-Y. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4504-y · Cited by 37
From Target Identification to Drug Development in Space: Using the Microgravity Assist
Braddock, M. (2019) · Current Drug Discovery Technologies · doi:10.2174/1570163816666190112150014 · Cited by 36
Kobayashi, T., Morimoto, T., Ito, K., Mawatari, M., & Shimazaki, T. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07118-0 · Cited by 35
“Denosumab and bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid are the most commonly used drugs for treating osteoporosis worldwide [1, 2].”
Negative association between Body Roundness Index and bone mineral density: insights from NHANES
Ding, Z., Zhuang, Z., Tang, R., Qu, X., Huang, Z., Maji, S., & Feng, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1448938 · Cited by 35
Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist
Boyce, E. G., Mai, Y., & Pham, C. J. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017748649 · Cited by 35
Long-term treatment strategies for postmenopausal osteoporosis
Cosman, F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000509 · Cited by 35
Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development
Zhang, Y., Luo, G., & Yu, X. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180801145614 · Cited by 35
Mori, T., Crandall, C. J., & Ganz, D. A. (2019) · JBMR Plus · doi:10.1002/jbm4.10233 · Cited by 35
Siu, A. L., Allore, H. G., Brown, D., Charles, S. T., & Lohman, M. C. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0961 · Cited by 35
Ciacci, C., Bilancio, G., Russo, I., Iovino, P., Cavallo, P., Santonicola, A., Bucci, C., Cirillo, M., & Zingone, F. (2020) · Nutrients · doi:10.3390/nu12040929 · Cited by 28
The gut–bone axis in osteoporosis: a multifaceted interaction with implications for bone health
Gu, C., Du, H., Li, N., Zhou, Y., Li, S., Sun, Y., Han, Y., Xu, X., & Li, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569152 · Cited by 34
Screening Gene Knockout Mice for Variation in Bone Mass: Analysis by μCT and Histomorphometry
Rowe, D. W., Adams, D. J., Hong, S.-H., Zhang, C., Shin, D., Rydzik, C. R., Chen, L., Wu, Z., Garland, G., Godfrey, D. A., et al. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0421-4 · Cited by 34
Huang, D., Wang, Y., Lv, J., Yan, Y., Hu, Y., Liu, C., Zhang, F., Wang, J., & Hao, D. (2020) · PeerJ · doi:10.7717/peerj.9009 · Cited by 34
“Osteoporotic fracture (OF) caused by OP is a major hazard and is one of the main causes of disability and death in older adults (Qaseem et al., 2017).”
BackgroundHow Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects?
Wibowo, E., Wassersug, R. J., Robinson, J. W., Matthew, A., McLeod, D. L., & Walker, L. M. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.12.006 · Cited by 34
Management of immune thrombocytopenia in women: current standards and special considerations
Rodeghiero, F., & Marranconi, E. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1711729 · Cited by 33
“Short intermittent courses of corticosteroids seem to be less prone to induce irreversible osteoporosis [59].”
BackgroundEffect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
Ha, J., Kim, J., Jeong, C., Lim, Y., Kim, M. K., Kwon, H.-S., Song, K., Kang, M. I., & Baek, K. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06388-w · Cited by 33
“Although raloxifene has a weaker effect on increasing bone density than bisphosphonates, it is an antiresorptive agent-proved vertebral antifracture efficacy [7, 33].”
BackgroundAssociation of air pollutants and osteoporosis risk: The modifying effect of genetic predisposition
Xu, C. Y., Weng, Z., Liu, Q., Xu, J., Liang, J., Li, W., Hu, J., Huang, T., Zhou, Y., & Gu, A. (2022) · Environment International · doi:10.1016/j.envint.2022.107562 · Cited by 33
Minodronate for the treatment of osteoporosis
Ohishi, T., & Matsuyama, Y. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s149236 · Cited by 33
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates
Black, D. M., Eastell, R., & Adams, A. L. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2029828 · Cited by 33
Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures
Ding, L., Hu, J., Wang, D., Liu, Q., Mo, Y., Tan, X., & Wen, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz023 · Cited by 32
Xu, Y., Chen, S., Huang, L., Han, W., Shao, Y., Chen, M., Zhang, Y., He, R., & Xie, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894832 · Cited by 32
“most frequently utilized agents for treating osteoporosis (Qaseem et al., 2017).”
BackgroundHong, P., Liu, R., Rai, S., Liu, J., Zhou, Y., Zheng, Y., & Li, J. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-03595-x · Cited by 32
Mazurov, V. I., Lesnyak, O. M., Belova, K. Y., Ershova, O. B., Zotkin, E. G., Marchenkova, L., Kochish, A. Y., ROZhINSKAYa, L. Y., & Skripnikova, I. A. (2019) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20192201157 · Cited by 32
Li, D., Dai, D., Wang, J., & Zhang, C. (2024) · Small · doi:10.1002/smll.202403907 · Cited by 31
Mohtadi, F. E., d’Arcy, R., Burke, J., Rosa, J. M. R. D. L., Gennari, A., Marotta, R., Francini, N., Donno, R., & Tirelli, N. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01348 · Cited by 31
The Role of Diet in Osteoporotic Fracture Healing: a Systematic Review
Chiavarini, M., Naldini, G., & Fabiani, R. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00573-8 · Cited by 31
Bar, M., Ott, S. M., Lewiecki, E. M., Sarafoglou, K., Wu, J. Y., Thompson, M., Vaux, J. J., Dean, D. R., Saag, K. G., Hashmi, S. K., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.07.001 · Cited by 31
Ren, Z., Raut, N. A., Lawal, T. O., Patel, S., Lee, S. M., & Mahady, G. B. (2021) · Phytotherapy Research · doi:10.1002/ptr.7271 · Cited by 31
“…mass, they also are associated with serious adverse events, including atypical femoral fractures, dementia, hypocalcemia, increased risk of coronary heart disease, osteonecrosis of the jaw, upper gastrointestinal symptoms, and stroke (Kanis et al., 2013; Qaseem et al., 2017; Rossini et al., 2016).”
BackgroundInfluentialWang, G., Fang, Z.-B., Li, H., Liu, D., Chu, S.-F., & Zhao, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.994406 · Cited by 31
Colon-Emeric, C. S., Pieper, C. F., Houtven, C. H. V., Grubber, J. M., Lyles, K. W., LaFleur, J., & Adler, R. A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.06.024 · Cited by 31
Leslie, W. D., Morin, S. N., Martineau, P., Bryanton, M., & Lix, L. M. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3813 · Cited by 31
Papadakis, I. S., Spanou, A., & Kalyvas, D. G. (2020) · Journal of Oral Implantology · doi:10.1563/aaid-joi-d-19-00088 · Cited by 30
Li, Y., Liem, Y., Dall’Ara, E., Sullivan, N., Ahmed, H., Blom, A. W., & Sharif, M. (2021) · Journal of Orthopaedic Research® · doi:10.1002/jor.25018 · Cited by 30
“9 years).(34,35) Patients with secondary OP due to prolonged use of corticosteroids, or on medications that affect bone metabolism were excluded.”
BackgroundIolascon, G., Alessandro de, S. I. R. E., Curci, C., Paoletta, M., Liguori, S., Calafiore, D., Gimigliano, F., & Moretti, A. (2021) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.21.06581-3 · Cited by 30
Substance P, A Promising Therapeutic Target in Musculoskeletal Disorders
Ko, K. R., Lee, H. I., Han, S.-H., Ahn, W., Kim, H. K., Kim, I.-S., Jung, B. S., & Lee, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052583 · Cited by 29
“Supplemental calcium and vitamin D are also used [101,102].”
BackgroundLi, T., Tao, Z.-S., Liu, H., Ren, M., Zhou, Z., Jiang, W.-K., & Yang, M. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-03695-8 · Cited by 29
Update on osteoporosis treatment
Nogués, X., & Martínez-Laguna, D. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.03.011 · Cited by 29
Bone formation recovery with gold nanoparticle-induced M2 macrophage polarization in mice
Bai, X., Chen, D., Dai, Y., Liang, S., Song, B., Guo, J., Dai, B., Zhang, D., & Feng, L. P. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102457 · Cited by 29
Huang, X., Ni, B., Li, Q., Liu, M., Zhao, M., Zhang, Y., Shi, X., & Wang, W. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073262645231121025911 · Cited by 28
Dong, S., Zhu, J., Yang, H., Huang, G., Zhao, C., & Yuan, B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.874672 · Cited by 28
Nelson, A. J., Roy, S. K., Warren, K. J., Janike, K., Thiele, G. M., Mikuls, T. R., Romberger, D. J., Wang, D., Swanson, B. J., & Poole, J. A. (2018) · Journal of Immunotoxicology · doi:10.1080/1547691x.2018.1460425 · Cited by 28
“…are likely to be of limited clinical value as estrogen replacement is not recommended for osteoporosis treatment in post-menopausal women because of its potential increased risk for venous thromboembolic disorders, cardiac events, stroke, and breast and endometrial cancer (Qaseem et al. 2017).”
BackgroundPan, J., Huang, C., Chen, G., Cai, Z., & Zhang, Z. (2018) · MedChemComm · doi:10.1039/c8md00187a · Cited by 27
RetractedReview on the protective activity of osthole against the pathogenesis of osteoporosis
Chen, J., Liao, X., & Gan, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1236893 · Cited by 27
“For example, the common adverse effects of bisphosphonates by oral administration are dysphagia, abdominal pain, nausea, flatulence, constipation or diarrhea, acid regurgitation, taste distortion, esophageal ulcers, and gastritis (Schuiling et al., 2011; Qaseem et al., 2017; Akkawi and Zmerly, 2018).”
BackgroundLi, J., Jia, H., Liu, Z., & Xu, K. (2024) · Bone · doi:10.1016/j.bone.2024.117253 · Cited by 27
Blackcurrant Supplementation Improves Trabecular Bone Mass in Young but Not Aged Mice
Sakaki, J. R., Melough, M. M., Lee, S. G., Kalinowski, J., Koo, S. I., Lee, S., & Chun, O. K. (2018) · Nutrients · doi:10.3390/nu10111671 · Cited by 27
Han, J., Li, L., Zhang, C., Huang, Q., Wang, S., Li, W., Zong, J., Li, L., Zhao, Z., ZengLiang, Z., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772944 · Cited by 27
After the fall: improving osteoporosis treatment following hip fracture
Kuiper, B. W., Graybill, S. D., Tate, J. M., Kaufman, N., & Bersabe, D. K. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4416-x · Cited by 27
Avenell, A., Bolland, M. J., Gamble, G. D., & Grey, A. (2024) · Accountability in Research · doi:10.1080/08989621.2022.2082290 · Cited by 26
“Four of the remaining 42 publications emailed had also publicly alerted their readers (Herrmann et al. 2007; McCarus 2006; Murad et al. 2012; Qaseem et al. 2017).”
BackgroundZingone, F., & Ciacci, C. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.04.005 · Cited by 26
Shieh, A., Karlamangla, A. S., Huang, M., Han, W., & Greendale, G. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab279 · Cited by 26
Xie, B., Zhou, H., Liu, H., Liao, S., Zhou, C., & Xu, D. (2022) · Phytotherapy Research · doi:10.1002/ptr.7711 · Cited by 26
“GIOP is treated with bisphosphonates, which include alendronate and zoledronic acid (Buckley & Humphrey, 2018; Qaseem et al., 2017).”
BackgroundAnwar, A., Sapra, L., Gupta, N., Ojha, R. P., Verma, B., & Srivastava, R. K. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31036 · Cited by 26
“Clinical data demonstrate the involvement of presently available antiresorptive agents, especially bisphosphonates and denosumab, and anabolic compounds like teriparatide, in the prevention of vertebral, nonvertebral, and hip fractures in postmenopausal females (Qaseem et al., 2017).”
BackgroundWang, Y., Dai, J., Zhu, Y., Zhong, W., Lu, S., Chen, H., & Chai, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23677 · Cited by 26
“Consequently, there is a search for new dual-action therapeutic agents for osteoporosis that simultaneously suppress bone resorption and accelerate bone formation [1, 2].”
BackgroundTan, X., Wen, F., Yang, W., Xie, J.-Y., Ding, L., & Mo, Y. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001321 · Cited by 26
“Pharmacologic treatments for postmenopausal osteoporosis mainly include bisphosphonates (eg, alendronate, risedronate, and zoledronic acid), peptide hormones (eg, teriparatide), selective estrogen receptor modulators (eg, raloxifene), new biologic agent (denosumab), and supplemental calcium and vitamin D according to…”
BackgroundLi, G., Compston, J. E., Leslie, W. D., Thabane, L., Παπαϊωάννου, Α., Lau, A. N., Wang, X., Qin, C., Chen, B., Chen, M., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4139 · Cited by 26
“To evaluate the robustness of findings, we conducted three sensitivity analyses by: (i) performing a competing risk analysis after taking all-cause mortality as a competing event for MOF, in which the data on mortality were collected through contact with the women’s husbands, family members or friends, and via electro…”
MethodYamori, M., Tamura, M., Mikami, M., Mori, T., Noi, M., Machida, Y., Koshinuma, S., & Yamamoto, G. (2021) · International Dental Journal · doi:10.1016/j.identj.2020.12.005 · Cited by 26
Association of gout with osteoporotic fractures
Wang, Y., Zhou, R., Zhong, W., Hu, C., Lu, S., & Chai, Y. (2018) · International Orthopaedics · doi:10.1007/s00264-018-4033-5 · Cited by 26
Ding, L., Wen, F., Wang, H., Wang, D.-H., Liu, Q., Mo, Y., Tan, X., Qiu, M., & Hu, J.-X. (2020) · Osteoporosis International · doi:10.1007/s00198-019-05183-4 · Cited by 25
Physician-Reported Barriers to Osteoporosis Screening: A Nationwide Survey
Choksi, P. U., Gay, B. L., Haymart, M. R., & Papaleontiou, M. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.05.001 · Cited by 25
Zhu, B., Hu, S., Guo, J., Dong, Z., Dong, Y., & Li, F. (2023) · BMC Public Health · doi:10.1186/s12889-023-15947-7 · Cited by 26
“Uncontrollable risk factors for osteoporosis include advanced age, female sex, menopause, family history, and race, while controllable risk factors include low body weight, low sex hormones, smoking, excessive drinking, lack of physical activity, dietary calcium and vitamin D deficiency [1, 7, 8].”
BackgroundZhang, B., He, W., Pei, Z., Guo, Q., Wang, J., Sun, M., Yang, X., Ariben, J., Li, S., Feng, W., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102479 · Cited by 25
“Osteoporotic fractures, which frequently transpire during minor trauma or routine activities, represent a grave outcome of OP(Qaseem et al., 2017)and stand as a prominent contributor to disability and mortality among elderly individuals(Black and Rosen, 2016).”
BackgroundMehta, S. D., & Sebro, R. (2019) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-019-01933-1 · Cited by 25
Wen, F., Du, H., Ding, L., Hu, J., Huang, Z., Huang, H., Li, K., Mo, Y., & Kuang, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234123 · Cited by 25
“…evidence deriving from newly-published RCTs [22,43,50,51,57]mainly involving two newly approved drugs (namely, romosozumab [23] and abaloparatide [24]) and a new drug intervention (namely, zoledronate 5 mg per 18 months), which could become a strong basis of updating the 2017 ACP guideline [13].”
InfluentialMcGrath, L. J., Spangler, L., Curtis, J. R., Ehrenstein, V., Sørensen, H. T., Saul, B., Levintow, S. N., Reams, D., Bradbury, B. D., & Brookhart, M. A. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5037 · Cited by 25
Başgöz, B. B., İnce, S., Safer, U., Naharcı, M. İ., & Taşçı, İ. (2020) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2020.3803 · Cited by 25
Wu, C., Hung, W., Chang, I., Tsai, T., Chang, Y., McCloskey, E. V., Watts, N. B., McClung, M. R., Huang, C., Chen, C., et al. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100729 · Cited by 25
“Results of such studies have led to a universal acceptance of pharmacologic treatment for osteoporosis with fragility fractures and recommendations by current guidelines (Qaseem et al., 2017).”
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 25
Zemp, J., Erol, C., Kaiser, E., Aubert, C. E., Rodondi, N., & Moutzouri, E. (2025) · Archives of Public Health · doi:10.1186/s13690-025-01709-x · Cited by 26
“Nearly one third (9/31) of these guidelines were aimed to people with osteoporosis [17, 19–26]one third (9/31) recommended supplementation for the older population (age range > 65-75years) [5, 19–21, 27–31] and over half”
Autophagy in osteoporosis: Relation to oxidative stress
Ezzat, S., Louka, M. L., Zakaria, Z. M., Nagaty, M. M., & Metwaly, R. G. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27552 · Cited by 24
“Old age and female sex predominance in the osteoporotic group was in accordance with current epidemiological data.(15) Real‐time PCR was used to assess relative expression of Atg7 and SOD2 genes in bone tissue samples and significant difference in expression was found between osteoporotic and non‐osteoporotic groups (…”
ResultMondočková, V., Kováčová, V., Zemanová, N., Babikova, M., Martiniaková, M., Galbavy, D., & Omelka, R. (2023) · Genes · doi:10.3390/genes14010193 · Cited by 24
“The most frequently used SERM in postmenopausal osteoporotic women is raloxifene [28,29].”
Sugimoto, T., Inoue, D., Maehara, M., Oikawa, I., Shigematsu, T., & Nishizawà, Y. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0977-1 · Cited by 24
Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats
Xu, B., He, Y., Lu, Y., Ren, W., Shen, J., Wu, K., Xu, K., Wu, J., & Hu, Y. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.013 · Cited by 24
Powell, K. M., Skaggs, C., Pulliam, A. N., Berman, A. G., Allen, M. R., & Wallace, J. M. (2019) · Bone · doi:10.1016/j.bone.2019.06.018 · Cited by 24
“The estrogen receptor binding also prevents usage in some at-risk patient populations including children, specifically those with OI [43,44].”
BackgroundInterleukin-10-Producing B Cells Help Suppress Ovariectomy-Mediated Osteoporosis
Wang, Y., Zhang, W., Lim, S.-M., Xu, L., & Jin, J. (2020) · Immune Network · doi:10.4110/in.2020.20.e50 · Cited by 24
Wiesner, A., Szuta, M., Galanty, A., & Paśko, P. (2021) · Foods · doi:10.3390/foods10040720 · Cited by 23
“Although the overall effect of calcium, or vitamin D alone, on the reduction of fracture risk remains unclear [13,20], the supplementation of both substances is currently recommended for patients at high risk of calcium and vitamin D insufficiency, and in those treated for osteoporosis [21].”
BackgroundFATORES DE RISCO, DIAGNÓSTICO E ABORDAGENS TERAPÊUTICAS DA OSTEOPOROSE: UMA REVISÃO ATUALIZADA
Oliveira, C. W. D. M., Santos, A. D. S., Saraiva, C. D. V. S., del Corsso, C., de Sousa, M. B. V., Caracas, M. M. T., Carvalho, L. F. L., Handaous, H. R., Barreto, M. D. A., & Menezes, R. A. S. (2025) · Revista Contemporânea · doi:10.56083/rcv5n2-056 · Cited by 23
Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
Chen, Y., Zhu, J. W., Zhou, Y., Peng, J., & Wang, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.588095 · Cited by 24
Laur, O., Weaver, M. J., Bridge, C. P., Chow, E., Rosenthal, M. H., Bay, C. P., Javedan, H., Harris, M. B., & Khurana, B. (2021) · Skeletal Radiology · doi:10.1007/s00256-021-03951-0 · Cited by 23
“1% and thus represents an attractive point of intervention as osteoporosis is frequently underdiagnosed and undertreated, especially in men [38].”
BackgroundZhou, C., Shen, S., Zhang, M., Luo, H., Zhang, Y., Wu, C., Zeng, L., & Ruan, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1235081 · Cited by 23
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.